A5015458204- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Cancer Cells and Metastasis
- Colorectal and Anal Carcinomas
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Hepatocellular Carcinoma Treatment and Prognosis
- Vascular Anomalies and Treatments
- Voice and Speech Disorders
- Tracheal and airway disorders
- Computational Drug Discovery Methods
- Pharmacogenetics and Drug Metabolism
- Colorectal Cancer Surgical Treatments
- HIV Research and Treatment
- Intracranial Aneurysms: Treatment and Complications
- Animal Nutrition and Physiology
- HIV-related health complications and treatments
- Traumatic Brain Injury and Neurovascular Disturbances
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- Immune cells in cancer
- Chemical Reactions and Isotopes
- Neurosurgical Procedures and Complications
- Meat and Animal Product Quality
University Medical Center Utrecht
2013-2024
Utrecht University
2019-2024
Heidelberg University
2021
University Hospital Heidelberg
2021
Diakonessenhuis hospital
2016
Background Poor prognosis in colon cancer is associated with a high content of cancer-associated fibroblasts (CAFs) and an immunosuppressive tumor microenvironment. The relationship between these two features incompletely understood. Here, we aimed to generate model system for studying the interaction cells CAFs their effect on immune-related cytokines T cell proliferation. Methods were isolated from liver metastases immortalized prolong lifespan improve robustness reproducibility....
Abstract Background The inability to predict treatment response of colorectal cancer patients results in unnecessary toxicity, decreased efficacy and survival. Response testing on patient-derived organoids (PDOs) is a promising biomarker for efficacy. aim this study optimize PDO drug screening methods correlation with patient explore the potential responses standard chemotherapies. Methods We optimized screen 5–11 PDOs per condition complete set 23 from treated metastatic (mCRC). were...
Abstract Background Patients who develop early extrahepatic recurrence (EHR) may not benefit from local treatment of colorectal liver metastases (CRLMs). This study aimed to a prediction model for EHR after CRLMs using national data set. Methods A Cox regression was developed and validated internally on patients had with curative intent. Performance assessment included calibration, discrimination, net benefit, generalizability by internal–external cross-validation. The prognostic relevance...
Current knowledge on prognostic biomarkers (especially BRAFV600E /RAS mutations) in metastatic colorectal cancer (mCRC) is mainly based mCRC patients with proficient mismatch repair (pMMR) tumors. It uncertain whether these have the same value deficient (dMMR) This observational cohort study combined a population-based Dutch (2014-2019) and large French multicenter (2007-2017). All histologically proven dMMR tumor were included. In our real-world data of 707 patients, 438 treated first-line...
Metastatic colorectal cancer patients with deficient mismatch repair (dMMR mCRC) benefit from immunotherapy. Interpretation of the single-arm immunotherapy trials is complicated by insignificant survival data during systemic non-immunotherapy. We present on a large, comprehensive cohort dMMR mCRC patients, treated or without non-immunotherapy.Two hundred and eighty-one (n = 54 three prospective Phase 3 CAIRO trials; n 227 Netherlands Cancer Registry). Overall was analysed diagnosis (OS),...
Context As life expectancy improves among Human Immunodeficiency Virus (HIV) patients, renal and cardiovascular diseases are increasingly prevalent in this population. Renal disease mutual risk factors characterized by albuminuria. Understanding the interactions between HIV, is first step tackling new therapeutic frontier HIV. Methods In a rural primary health care centre, 903 HIV-infected adult patients were randomly selected data on HIV-infection collected. Glomerular filtration rate...
Optimized surgical techniques and systemic therapy have increased the number of patients with colorectal liver metastases (CRLM) eligible for local treatment. To increase postoperative survival, we need to stratify customize therapy. Most clinical risk scores (CRSs) which predict prognosis after CRLM resection were based on outcome studies in specialized centers, this may hamper generalizability these CRSs unselected populations underrepresented subgroups. We aimed externally validate two a...
The effect of low environmental temperature on the humoral immune response to sheep red blood cells (SRBC) was investigated in relation energy metabolism. Two experiments were done with 3- 6-week-old pullets using two climate respiration chambers. During both a standard regimen constant 25 C maintained one chamber, whereas other chamber 10 (Experiment 1) or fluctuated between 5 15 2). relative humidity held at 70% all regimens. Feed allowance such that growth rates temperatures within...
DNA mismatch repair deficiency (dMMR) in metastatic colorectal cancer (mCRC) is associated with poor survival and a response to systemic treatment. However, it unclear whether dMMR results tumor cell-intrinsic state of treatment resistance, or alternative mechanisms play role. To address this, we generated cohort MMR-proficient -deficient Patient-Derived Organoids (PDOs) tested their commonly used drugs the mCRC, including 5-fluorouracil (5-FU), oxaliplatin, SN-38, binimetinib, encorafenib,...
Predicting prognosis in refractory metastatic colorectal cancer (mCRC) patients is needed to guide decision making. The Colon Life nomogram was developed predict 12-week mortality mCRC patients. aim of this study validate the last line/refractory receiving trifluridine/tipiracil (FTD/TPI) daily practice. validation cohort consists 150 QUALITAS patients, an observational substudy Prospective Dutch CRC cohort, who were treated with FTD/TPI between 2016 and 2019. Model performance assessed on...
Abstract Introduction: The inability to predict treatment response results in unnecessary toxicity, decreased efficacy and survival. There is a clinical need for an effective biomarker select patients cancer treatment. A promising testing on patient-derived organoids (PDOs). For metastatic colorectal (mCRC), larger prospective studies are needed evaluate the predictive value of standardized PDO screens. Methods: OPTIC ongoing multicenter trial (NL61668.041.17, started 2018) that will tumor...
It is unclear whether curative-intent local therapy of metastases similar benefit for the biological distinct subgroup patients with deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC) compared proficient (pMMR) mCRC.In this nationwide study, recurrence-free (RFS) and overall survival (OS) were analyzed in dMMR versus pMMR mCRC who underwent treatment between 2015 2018. Subgroup analyses performed resection liver (CRLM) cytoreductive surgery ± hyperthermic intraperitoneal...
Abstract Introduction: Data on survival of patients with MSI mCRC treated systemic non-immunotherapy are scarce, which complicates the interpretation recent immunotherapy trials. Our study examined in a retrospective observational cohort. Methods: We performed involving 186 (n=54 from phase 3 CAIRO, CAIRO2 and CAIRO3 trials n=132 The Netherlands Cancer Registry 2015 2016). Overall diagnosis (OS), start first-line (OS1) second-line therapy (OS2) to death any cause were examined....
Abstract Patient-derived organoids (PDOs) are increasingly adopted in preclinical research. PDOs, or HUB Organoids®, directly established from patient tissue, faithfully recapitulate disease, and effectively bridge the gap between lab clinic, bringing a “patient lab®”. PDOs can also revolutionize clinical research because they predict response to standard-of-care (SoC) compounds. However, there is an urgent need refine assay conditions evaluate activity of SoC drugs with different mechanisms...
Abstract Background The inability to predict treatment response of colorectal cancer patients results in unnecessary toxicity, decreased efficacy and survival. Response testing on patient-derived organoids (PDOs) is a promising biomarker for efficacy. aim this study optimize PDO drug screening methods correlation with patient explore the potential responses standard chemotherapies. Methods We optimized screen 5–11 PDOs per condition complete set 23 from treated metastatic (mCRC). were...
Abstract Colorectal cancer (CRC) is the third leading cause of and cancer-related death. A large fraction CRC patients diagnosed with de novo metastatic disease do not benefit from standard care but still experience substantial side effects. Therefore, there urgency for a new model to predict clinical response. Adult epithelial stem cell (ASC) -derived organoids are proving be major breakthrough in pre-clinical models. ASC-derived can developed healthy as well diseased tissue, including...